In this study, we examined the prevalence of CDKN2A MUT and DEL in 25,755 tumor samples from 33 cancer types in the MSK-MetTropism cohort and discovered associations between CDKN2A MUT or DEL and clinical outcomes in pan-cancer patients with/without ICIs treatment. Here, CDKN2A is linked to neoplasm.